A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus

NCT06256549 | Unknown Phase 2

• 1 other identifier: GL-GLP-CH2004
• Study Type: interventional
• Target: 272
• Locations: 1 country
• Sites: 1

Brief Summary

This study was a multicenter, randomized, parallel and controlled study in adult patients with T2DM to evaluate the efficacy, safety (including immunogenicity) and pharmacokinetics of GZR18 injection in adult patients with T2DM.

Conditions

Type 2 Diabetes

Outcome Measures

Primary Outcomes (1)

• Compared with Semaglutide, the changes of HbA1c compared with baseline after continuous administration of GZR18 injection for 24 weeks

  24 weeks

Secondary Outcomes (2)

• HbA1c compliance rate (< 7.0% and ≤ 6.5% of patients)

  24 weeks

• The overall incidence of adverse events and the incidence of serious adverse events

  27 weeks

Study Arms (2)

GZR18

EXPERIMENTAL

GZR18 injection s.c.

Drug: GZR18

Semaglutide

ACTIVE COMPARATOR

Semaglutide injection s.c.

Drug: Semaglutide

Interventions

GZR18 DRUG

Titrated to low dose or middle or high dose

GZR18

Semaglutide DRUG

Titrated to 1.0 mg once a week

Semaglutide

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• (1) Chinese adults, male or female aged between 18 and 75 (including both ends).
• (2) According to the diagnostic and classification criteria of diabetes issued by the World Health Organization (WHO) in 1999, and the supplementary diagnostic criteria of WHO in 2011, type 2 diabetes was diagnosed for more than 3 months.
• (3) Lifestyle intervention and / or unregulated use of antidiabetic drugs within 3 months before screening, or stable use of less than 3 oral hypoglycemic drugs within 3 months before screening.
• (4) HbA1c (HbA1c) ≥ 7.0% and ≤ 11% during screening.
• (5) Body mass index (BMI) ≥ 18.5 kg/m2.
• (6) There is no birth plan within 6 months from the signing of informed consent to the last administration, and those who voluntarily take effective contraceptive measures and have no sperm donation plan. Fertile women are not breastfeeding, and the screening and baseline pregnancy tests must be negative.
• (7) Patients fully understand the purpose, nature, methods and possible adverse reactions of the trial, can communicate well with researchers, and can understand and comply with the requirements of this study. During the study, they can maintain a stable diet and exercise lifestyle, and voluntarily sign an informed consent form to enter this study.

You may not qualify if:

• (1) Known or suspected to be allergic to GLP-1 drugs or their excipients, or have contraindications to their use.
• (2) Those who participated in clinical trials of other drugs or devices within 3 months before were screened and given treatment.
• (3) Surgery that can lead to weight instability was performed within 2 months before screening, or non-diabetic drugs that affect weight are currently being used or are in the weight loss program and are not in the maintenance stage.
• (4) History of alcohol or drug abuse, or positive results of pre-random drug abuse screening (urine screening).
• (5) Continuous use of insulin for more than 14 days in one year before screening (the time for gestational diabetes to receive insulin treatment is not within this limit); GLP-1RA drugs were used in the first 6 months; dipeptidyl peptidase-4 (DPP-4) inhibitors were used in the first month.
• (6) Growth hormone and other drug treatments determined by researchers to affect insulin levels were performed within 3 months before screening.
• (7) Diabetic ketoacidosis, diabetic lactic acidosis or hyperosmotic nonketotic diabetic coma within 6 months before screening.

Sponsors & Collaborators

• Gan and Lee Pharmaceuticals, USA: lead

Study Sites (1)

Gan & Lee Pharmaceuticals Co., Ltd

Beijing, China

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

semaglutide

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Officials

• Liyuan Zhao, Ph.D

  Gan & Lee Pharmaceuticals.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 5, 2024
• First Posted: February 13, 2024
• Study Start: August 9, 2023
• Primary Completion: July 20, 2024
• Study Completion: July 20, 2024
• Last Updated: February 23, 2024

Record last verified: 2024-01

Locations

CN (1)